Commitments and Contingencies - Claims and Patent License Agreement (Details) $ / shares in Units, € in Thousands |
12 Months Ended | |||
|---|---|---|---|---|
|
Dec. 31, 2024
EUR (€)
|
Dec. 31, 2019
USD ($)
$ / shares
|
Dec. 31, 2018
USD ($)
$ / shares
|
Dec. 31, 2025
claim
|
|
| Commitments and Contingencies | ||||
| Shares issued in the period | € | € 71,633 | |||
| Claims known to management related to activities of company | claim | 0 | |||
| Agreement with Ionis Pharmaceuticals to license QR-1123 | ||||
| Commitments and Contingencies | ||||
| Collaborative arrangement, upfront payment made in ordinary shares to counterparty | $ | $ 3,501,000 | $ 2,500,000 | ||
| Collaborative arrangement, price per share paid to counterparty | $ / shares | $ 9.43 | $ 22.23 | ||
| Collaboration Agreement, premium on share price paid | 20.00% | |||
| Collaboration agreement, measurement period for volume weighted average price per share | 20 days | |||